Corcept Therapeutics Analyst Ratings
Corcept Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 48.32% | Truist Securities | $29 → $38 | Upgrades | Hold → Buy |
| 11/02/2023 | 32.71% | HC Wainwright & Co. | $32 → $34 | Maintains | Buy |
| 10/02/2023 | 13.19% | Truist Securities | → $29 | Reiterates | Hold → Hold |
| 08/25/2023 | 36.61% | Canaccord Genuity | $34 → $35 | Maintains | Buy |
| 08/03/2023 | 21% | Piper Sandler | $27 → $31 | Maintains | Overweight |
| 08/03/2023 | 13.19% | Truist Securities | $26 → $29 | Maintains | Hold |
| 08/03/2023 | 24.9% | HC Wainwright & Co. | $30 → $32 | Maintains | Buy |
| 05/26/2023 | 1.48% | Truist Securities | $28 → $26 | Maintains | Hold |
| 05/04/2023 | 17.1% | HC Wainwright & Co. | → $30 | Reiterates | → Buy |
| 04/11/2023 | -2.42% | SVB Leerink | → $25 | Initiates Coverage On | → Market Perform |
| 04/04/2023 | 5.39% | Piper Sandler | → $27 | Initiates Coverage On | → Overweight |
| 03/08/2023 | 24.9% | Canaccord Genuity | $33 → $32 | Maintains | Buy |
| 03/01/2023 | 17.1% | HC Wainwright & Co. | → $30 | Reiterates | → Buy |
| 02/15/2023 | -14.13% | Jefferies | $35 → $22 | Downgrades | Buy → Hold |
| 12/09/2022 | 17.1% | HC Wainwright & Co. | $33 → $30 | Maintains | Buy |
| 11/08/2022 | 9.29% | Truist Securities | $30 → $28 | Maintains | Hold |
| 08/04/2022 | 28.81% | HC Wainwright & Co. | $29 → $33 | Maintains | Buy |
| 08/01/2022 | 17.1% | Truist Securities | → $30 | Downgrades | Buy → Hold |
| 02/02/2022 | 17.1% | Canaccord Genuity | → $30 | Initiates Coverage On | → Buy |
| 01/28/2022 | 17.1% | Truist Securities | → $30 | Initiates Coverage On | → Buy |
| 06/23/2021 | 13.19% | HC Wainwright & Co. | $32 → $29 | Maintains | Buy |
| 11/27/2020 | 24.9% | HC Wainwright & Co. | $22 → $32 | Maintains | Buy |
| 11/04/2020 | -14.13% | HC Wainwright & Co. | $18 → $22 | Maintains | Buy |
| 08/05/2020 | -37.55% | Jefferies | → $16 | Downgrades | Buy → Hold |
| 02/21/2020 | -41.45% | Cantor Fitzgerald | $14 → $15 | Reiterates | → Neutral |
| 09/24/2019 | -21.94% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 09/06/2019 | -29.74% | HC Wainwright & Co. | → $18 | Initiates Coverage On | → Buy |
| 02/01/2019 | -45.36% | Cantor Fitzgerald | $20 → $14 | Downgrades | Overweight → Neutral |
| 12/12/2018 | 13.19% | Cantor Fitzgerald | $17 → $29 | Upgrades | Neutral → Overweight |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/06/2023 | 48.32% | Truist 證券 | 29 美元 → 38 美元 | 升級 | 持有 → 買入 |
| 11/02/2023 | 32.71% | HC Wainwright & Co. | 32 美元 → 34 美元 | 維護 | 購買 |
| 2023 年 2 月 10 日 | 13.19% | Truist 證券 | → 29 美元 | 重申 | 按住 → 按住 |
| 08/25/2023 | 36.61% | Canaccord Genu | 34 美元 → 35 美元 | 維護 | 購買 |
| 08/03/2023 | 21% | 派珀·桑德勒 | 27 美元 → 31 美元 | 維護 | 超重 |
| 08/03/2023 | 13.19% | Truist 證券 | 26 美元 → 29 美元 | 維護 | 保持 |
| 08/03/2023 | 24.9% | HC Wainwright & Co. | 30 美元 → 32 美元 | 維護 | 購買 |
| 05/26/2023 | 1.48% | Truist 證券 | 28 美元 → 26 美元 | 維護 | 保持 |
| 05/04/2023 | 17.1% | HC Wainwright & Co. | → 30 美元 | 重申 | → 購買 |
| 04/11/2023 | -2.42% | SVB Leerink | → 25 美元 | 啓動覆蓋範圍開啓 | → 市場表現 |
| 04/04/2023 | 5.39% | 派珀·桑德勒 | → 27 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 03/08/2023 | 24.9% | Canaccord Genu | 33 美元 → 32 美元 | 維護 | 購買 |
| 03/01/2023 | 17.1% | HC Wainwright & Co. | → 30 美元 | 重申 | → 購買 |
| 02/15/2023 | -14.13% | 傑富瑞集團 | 35 美元 → 22 美元 | 降級 | 買入 → 持有 |
| 2022 年 9 月 12 日 | 17.1% | HC Wainwright & Co. | 33 美元 → 30 美元 | 維護 | 購買 |
| 2022 年 8 月 11 日 | 9.29% | Truist 證券 | 30 美元 → 28 美元 | 維護 | 保持 |
| 08/04/2022 | 28.81% | HC Wainwright & Co. | 29 美元 → 33 美元 | 維護 | 購買 |
| 08/01/2022 | 17.1% | Truist 證券 | → 30 美元 | 降級 | 買入 → 持有 |
| 02/02/2022 | 17.1% | Canaccord Genu | → 30 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 01/28/2022 | 17.1% | Truist 證券 | → 30 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/23/2021 | 13.19% | HC Wainwright & Co. | 32 美元 → 29 美元 | 維護 | 購買 |
| 11/27/2020 | 24.9% | HC Wainwright & Co. | 22 美元 → 32 美元 | 維護 | 購買 |
| 11/04/2020 | -14.13% | HC Wainwright & Co. | 18 美元 → 22 美元 | 維護 | 購買 |
| 2020 年 5 月 8 日 | -37.55% | 傑富瑞集團 | → 16 美元 | 降級 | 買入 → 持有 |
| 02/21/2020 | -41.45% | 坎託·菲茨傑拉德 | 14 美元 → 15 美元 | 重申 | → 中立 |
| 2019 年 9 月 24 日 | -21.94% | 傑富瑞集團 | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/06/2019 | -29.74% | HC Wainwright & Co. | → 18 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 02/01/2019 | -45.36% | 坎託·菲茨傑拉德 | 20 美元 → 14 美元 | 降級 | 超重 → 中性 |
| 12/12/2018 | 13.19% | 坎託·菲茨傑拉德 | 17 美元 → 29 美元 | 升級 | 中性 → 增持 |
What is the target price for Corcept Therapeutics (CORT)?
Corcept Therapeutics（CORT）的目標價格是多少？
The latest price target for Corcept Therapeutics (NASDAQ: CORT) was reported by Truist Securities on November 6, 2023. The analyst firm set a price target for $38.00 expecting CORT to rise to within 12 months (a possible 48.32% upside). 16 analyst firms have reported ratings in the last year.
Truist Securities於2023年11月6日公佈了Corcept Therapeutics（納斯達克股票代碼：CORT）的最新目標股價。該分析公司將目標股價定爲38.00美元，預計CORT將在12個月內上漲至38.00美元（可能上漲48.32％）。去年有16家分析公司公佈了評級。
What is the most recent analyst rating for Corcept Therapeutics (CORT)?
Corcept Therapeutics（CORT）的最新分析師評級是多少？
The latest analyst rating for Corcept Therapeutics (NASDAQ: CORT) was provided by Truist Securities, and Corcept Therapeutics upgraded their buy rating.
Corcept Therapeutics（納斯達克股票代碼：CORT）的最新分析師評級由Truist Securities提供，Corcept Therapeutics上調了買入評級。
When is the next analyst rating going to be posted or updated for Corcept Therapeutics (CORT)?
Corcept Therapeutics（CORT）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corcept Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corcept Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Corcept Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Corcept Therapeutics的最後一次評級是在2023年11月6日公佈的，因此你應該預計下一個評級將在2024年11月6日左右公佈。
Is the Analyst Rating Corcept Therapeutics (CORT) correct?
分析師對Corcept Therapeutics（CORT）的評級是否正確？
While ratings are subjective and will change, the latest Corcept Therapeutics (CORT) rating was a upgraded with a price target of $29.00 to $38.00. The current price Corcept Therapeutics (CORT) is trading at is $25.62, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的Corcept Therapeutics（CORT）評級已上調，目標股價爲29.00美元至38.00美元。Corcept Therapeutics（CORT）目前的交易價格爲25.62美元，超出了分析師的預測區間。